NeuroSense Therapeutics Ltd. (NASDAQ:NRSNW) Sees Significant Increase in Short Interest

NeuroSense Therapeutics Ltd. (NASDAQ:NRSNW) saw a significant growth in short interest in the month of March. As of March 15th, there was short interest totalling 4,200 shares, a growth of 740.0% from the February 29th total of 500 shares. Based on an average daily volume of 9,600 shares, the short-interest ratio is currently 0.4 days.

NeuroSense Therapeutics Price Performance

Shares of NRSNW traded down $0.14 during midday trading on Thursday, hitting $0.36. The company had a trading volume of 2,311 shares, compared to its average volume of 12,633. The company’s 50 day moving average price is $0.25 and its 200 day moving average price is $0.18. NeuroSense Therapeutics has a 52 week low of $0.07 and a 52 week high of $0.50.

About NeuroSense Therapeutics

NeuroSense Therapeutics Ltd., a clinical-stage biotechnology company, focuses on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases in the United States and internationally. Its lead product is PrimeC, an extended-release oral formulation of a fixed dose combination of ciprofloxacin and celecoxib for the treatment of amyotrophic lateral sclerosis.